



03-Jan-2023

Dear Colleague:

Our research site is currently recruiting adults to participate in a clinical trial for treatment-refractory Mycobacterium avium complex (MAC) lung disease. We would appreciate your help with identifying potential study participants.

Epetraborole is designed to work by blocking protein synthesis and is formulated as a daily oral regimen that will be taken in addition to the participants existing treatment.

This Phase 2/3 study is evaluating electronic patient-reported outcomes (ePRO)-based symptom responses, microbiological response, safety, tolerability, epetraborole pharmacokinetics, and the superiority of epetraborole + existing treatment vs. placebo + existing treatment. The clinicaltrials.gov number for this study is NCT05327803.

**Key eligibility criteria:**

- 18 years of age or older
- Diagnosed with treatment-refractory MAC lung disease with treatment of at least 2 antimycobacterial agents for at least 6 of the last 12 months
- At least 2 of the following ongoing symptoms at Screening: cough with sputum production, dry cough, chest congestion, hemoptysis, shortness of breath, fatigue, night sweats or unusual sweating
- No predominantly fibrocavitary MAC lung disease or radiographic presences of any cavity >3.0 cm in diameter
- Less than 5 year history of treatment-refractory MAC lung disease
- No history of CF or other inherited disorders of airway ciliary dysfunction, active allergic bronchopulmonary mycosis or concomitant pulmonary infection requiring antimicrobial therapy
- Expected to survive with continued antimycobacterial therapy and appropriate supportive care from Screening through the final study visit (up to 19 months)

If you have a patient who may be eligible for this study, please provide your patient with my contact information as soon as possible:

**Research Coordinators can be reached at either 973-972-1976 or 973-972-9100**

Thank you for your assistance.

Sincerely,

Amea Patrawalla, MD  
Principal Investigator  
MACrO2 Study  
macro2study.com

**AN2**Therapeutics

**M E D P A C E**